Viridian Therapeutics ... Booth in February 2006 and is headquartered in Waltham, MA.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...
Hosted on MSN1mon
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial DataShares of Viridian Therapeutics surged nearly 18% at the open on Monday to a nearly three-week high after the company reported promising trial data for its experimental drug veligrotug ...
and multiple FcRn inhibitor portfolio clinical catalysts - WALTHAM, Mass., January 08, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering ...
WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
WALTHAM, Mass., February 06, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for ...
WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class ...
- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) -- Conference call and webcast to be held... WALTHAM, Mass.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback